Skip to main content
. 2021 May 15;11(5):2159–2173.

Figure 2.

Figure 2

Overexpression of miR-22 inhibits liver tumor growth in mice. A. Process of miR-22 treatment in DEN/PB-mediated primary HCC model. B. qPCR analysis of miR-22 expression in tumor tissues from mice after lenti-ctrl or lenti-miR-22 treatment (n=4, P<0.0001). C. qPCR analysis of miR-22 expression in circulating T cells from mice after lenti-ctrl or lenti-miR-22 treatment (n=4, P<0.0001). D. Weight of liver from mice after lenti-ctrl or lenti-miR-22 treatment (n=5, P=0.0008). E. Number of tumors in mice after lenti-ctrl or lenti-miR-22 treatment (n=5, P=0.0093). F, H. E. staining of livers from mice after lenti-ctrl or lenti-miR-22 treatment. Scale bar =200 μm. Black arrows indicated the tumor area. The percent of tumor area was analyzed in each slides (n=5, P=0.0001). G. Process of miR-22 treatment in Hepa1-6 subcutaneous tumor model. H. miR-22 expression in subcutaneous tumors from lenti-ctrl or lenti-miR-22 treatment group (n=4, P<0.0001). I. miR-22 expression in circulating T cells from lenti-ctrl or lenti-miR-22 treatment group (n=4, P<0.0001). J. Image of tumors from lenti-ctrl or lenti-miR-22 treatment group. K. The curve of tumor volume from lenti-ctrl or lenti-miR-22 treatment group (n=5, **, P<0.01). L. The weight of tumors from lenti-ctrl or lenti-miR-22 treatment group (n=5, **, P=0.0014).